ACIU News

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine